About CurationHealth

When it comes to your health, or the health of someone close to you, it can feel like there’s just too much information out there. At CurationHealth, we get it. We focus on finding relevant and quality news stories about the big health care issues. And we help you make sense of it all.

1. Torous J, Chan SR, Yee-Marie Tan S, Behrens J, Mathew I, et al. Patient smartphone ownership and interest in mobile apps to monitor symptoms of mental health conditions: a survey in four geographically distinct psychiatric clinics. JMIR Ment Health....

  • Neuropsychopharmacology (subscription)
  • 0 views
  • View Source

THOUSAND OAKS, Calif., Sept. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), today...

The FDA approved sublingual film formulations of buprenorphine/naloxone -- as branded (Cassipa) and generic products -- at a new dosage of 16 mg buprenorphine/4 mg naloxone and indicated as...

It’s a devastating memory-wasting disease that has continually seen failure after failure in the clinic, but now a Florida medtech company is hoping it can seek out better Alzheimer’s treatments by...

  Welcome to FDAweb   Pay Per View Search our 62,416 - story database FREE   ...

The FDA granted Dthera Sciences breakthrough designation for its digital Alzheimer’s treatment,...

Dthera ™ Sciences, the leading digital therapeutic company focusing on the elderly and individuals with neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA)...

Dthera Sciences, a San Diego-based developer of clinical and consumer digital therapeutics for individuals with neurodegenerative conditions, announced today that its development stage intervention,...

The FDA granted de novo clearance to the first noninvasive device treatment for obsessive compulsive disorder, Brainsway’s transcranial magnetic stimulation system, adding a new therapy for adults...

The pilot study of Alzheimer's patients found that deep brain stimulation targeting frontal brain regions can reduce the overall performance decline typically seen in people with mild Alzheimer’ disease. By Alzheimer's Reading Room While most treatments...

A disparity between how many apolipoprotein E4 ( APOE4 ) carriers were in the highest-tested dose of BAN2401 versus how many were in the placebo group fueled controversy over the investigational...

Researchers from Massachusetts General Hospital have used a microfluidic device to incorporate neuroinflammation into a model of Alzheimer’s disease. It is hoped that the development will improve our...

Six days after activated microglia (red) were added to the outer chamber of the new microfluidic device, the inflammatory cells migrate through channels into the inner chamber, containing cultured...